Carfilzomib-Associated Cardiovascular Adverse Events
نویسندگان
چکیده
منابع مشابه
Basic mechanisms for adverse cardiovascular events associated with air pollution.
Air pollution is a significant cause of cardiovascular morbidity and mortality worldwide. Although the epidemiologic association between air pollution exposures and exacerbation of cardiovascular disease (CVD) is well established, the mechanisms by which these exposures promote CVD are incompletely understood. This review provides an overview of the components of air pollution, an overview of t...
متن کاملBisphosphonate-associated adverse events.
The adverse events of the nitrogen-containing bisphosphonates are reviewed. Oral bisphosphonates (alendronate, risedronate and ibandronate), mainly used for the treatment of osteoporosis, have been associated with adverse events from the upper gastrointestinal tract, acute phase response, hypocalcaemia and secondary hyperparathyroidism, musculoskeletal pain, osteonecrosis of the jaw and ocular ...
متن کاملAnticoagulation-associated adverse drug events.
PURPOSE Anticoagulant drugs are among the most common medications that cause adverse drug events (ADEs) in hospitalized patients. We performed a 5-year retrospective study at Brigham and Women's Hospital to determine clinical characteristics, types, root causes, and outcomes of anticoagulant-associated ADEs. METHODS We reviewed all inpatient anticoagulant-associated ADEs, including adverse dr...
متن کاملAdverse events associated with ERCP.
Vinay Chandrasekhara, MD, Mouen A. Khashab, MD, V. Raman Muthusamy, MD, FASGE, Ruben D. Acosta, MD, Deepak Agrawal, MD, MPH, David H. Bruining, MD, Mohamad A. Eloubeidi, MD, MHS, FASGE, Robert D. Fanelli, MD, FACS, FASGE, SAGES Representative, Ashley L. Faulx, MD, FASGE, Suryakanth R. Gurudu, MD, FASGE, Shivangi Kothari, MD, Jenifer R. Lightdale, MD, MPH, FASGE, NASPGHAN Representative, Bashar ...
متن کاملNonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.
PURPOSE Bortezomib (Velcade), a dipeptide boronate 20S proteasome inhibitor and an approved treatment option for multiple myeloma, is associated with a treatment-emergent, painful peripheral neuropathy (PN) in more than 30% of patients. Carfilzomib, a tetrapeptide epoxyketone proteasome inhibitor, currently in clinical investigation in myeloma, is associated with low rates of PN. We sought to d...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JAMA Oncology
سال: 2018
ISSN: 2374-2437
DOI: 10.1001/jamaoncol.2017.4519